Using this model, we provide novel evidence that the βA3/A1‐crystallin/PAT4/V‐ATPase complex is a potential therapeutic target for preventing or delaying the progression of dry AMD. This evidence concerns the gene SLC36A4 and dry age related macular degeneration.